{"filing":{"accession_number":"0001437749-26-023480","cik":"0001595248","ticker":"GNPX","company_name":"Genprex, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"gnpx20260630_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926023480/gnpx20260630_8k.htm"},"events":[{"id":17788,"run_id":15950,"accession_number":"0001437749-26-023480","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Genprex received a Nasdaq delisting notice on June 10, 2026, for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has requested a hearing before a Nasdaq Hearings Panel and is implementing a 1-for-22 reverse stock split effective July 16, 2026, to regain compliance.","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16396,"accession_number":"0001437749-26-023480","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Genprex received a Nasdaq delisting notice on June 10, 2026, for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has requested a hearing before a Nasdaq Hearings Panel and is implementing a 1-for-22 reverse stock split effective July 16, 2026, to regain compliance. This is a clear delisting risk disclosure under Item 8.01, with explicit language that \"If our Common Stock is delisted from Nasdaq, it could result in a corresponding material reduction in the price of our Common Stock\" and harm to capital-raising ability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T13:24:51.946807+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":17789,"run_id":15950,"accession_number":"0001437749-26-023480","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Genprex stockholders approved a 1-for-22 reverse stock split on June 18, 2026, which was effectuated via Certificate of Amendment filed July 13, 2026. The reverse split materially affects shareholder rights and capital structure by consolidating shares and altering per-share metrics.","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16393,"accession_number":"0001437749-26-023480","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 3.03 discloses a material modification to security holders' rights through a reverse stock split. The filing incorporates by reference Item 5.03 details regarding the reverse stock split. A reverse stock split materially affects the rights and economic interests of existing shareholders by consolidating shares and altering the per-share metrics, making this a governance event affecting capital structure and shareholder rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T13:24:51.946807+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16394,"accession_number":"0001437749-26-023480","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure reports a 1:22 reverse stock split approved by stockholders on June 18, 2026 and effectuated via Certificate of Amendment filed July 13, 2026. While a reverse split is a governance/capital structure matter (amendment to articles of incorporation), it is material to investors as it affects share count, trading price, and market perception. The event does not fit the specific categories of exec_departure, exec_appointment, or exec_compensation, making governance_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T13:24:51.946807+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":17790,"run_id":15950,"accession_number":"0001437749-26-023480","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"summary":"Genprex furnished an investor presentation under Regulation FD for use at meetings with investors, analysts, and others, to be made available on the company website.","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16395,"accession_number":"0001437749-26-023480","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This is a routine disclosure of an investor presentation under Regulation FD (Item 7.01), furnished but not filed. The filing explicitly states the presentation \"may be presented at meetings with investors, analysts, and others\" and will be available on the company website. This is a standard operational/communications disclosure without material business, financial, or governance consequences—it is administrative in nature and does not affect the total mix of information available to investors about the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T13:24:51.946807+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16393,"accession_number":"0001437749-26-023480","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 3.03 discloses a material modification to security holders' rights through a reverse stock split. The filing incorporates by reference Item 5.03 details regarding the reverse stock split. A reverse stock split materially affects the rights and economic interests of existing shareholders by consolidating shares and altering the per-share metrics, making this a governance event affecting capital structure and shareholder rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T13:24:51.946807+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-14"},{"id":16394,"accession_number":"0001437749-26-023480","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure reports a 1:22 reverse stock split approved by stockholders on June 18, 2026 and effectuated via Certificate of Amendment filed July 13, 2026. While a reverse split is a governance/capital structure matter (amendment to articles of incorporation), it is material to investors as it affects share count, trading price, and market perception. The event does not fit the specific categories of exec_departure, exec_appointment, or exec_compensation, making governance_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T13:24:51.946807+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-14"},{"id":16395,"accession_number":"0001437749-26-023480","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This is a routine disclosure of an investor presentation under Regulation FD (Item 7.01), furnished but not filed. The filing explicitly states the presentation \"may be presented at meetings with investors, analysts, and others\" and will be available on the company website. This is a standard operational/communications disclosure without material business, financial, or governance consequences—it is administrative in nature and does not affect the total mix of information available to investors about the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T13:24:51.946807+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-14"},{"id":16396,"accession_number":"0001437749-26-023480","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Genprex received a Nasdaq delisting notice on June 10, 2026, for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has requested a hearing before a Nasdaq Hearings Panel and is implementing a 1-for-22 reverse stock split effective July 16, 2026, to regain compliance. This is a clear delisting risk disclosure under Item 8.01, with explicit language that \"If our Common Stock is delisted from Nasdaq, it could result in a corresponding material reduction in the price of our Common Stock\" and harm to capital-raising ability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T13:24:51.946807+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-14"}]}